Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Buchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Muller-Tidow C et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27: 61–69.

    Article  Google Scholar 

  2. Gale RP, Cline MJ . High remission-induction rate in acute myeloid leukaemia. Lancet 1977; 1: 497–499.

    Article  CAS  Google Scholar 

  3. Stelljes M, Krug U, Beelen DW, Braess J, Sauerland MC, Heineke A et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol 2014; 32: 288–296.

    Article  Google Scholar 

  4. Buchner T, Berdel WE, Hiddemann W . Priming with granulocyte colony-stimulating factor—relation to high-dose cytarabine in acute myeloid leukemia. N Engl J Med 2004; 350: 2215–2216.

    Article  Google Scholar 

  5. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.

    Article  Google Scholar 

  6. Falini B, Macijewski K, Weiss T, Bacher U, Schnittger S, Kern W et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood 2010; 115: 3776–3786.

    Article  CAS  Google Scholar 

  7. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911–1918.

    CAS  Google Scholar 

  8. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2010; 27: 263–270.

    Article  Google Scholar 

  9. Rosthoj S, Andersen PK, Abildstrom SZ . SAS macros for estimation of the cumulative incidence functions based on a Cox regression model for competing risks survival data. Comput Methods Prog Biomed 2004; 74: 69–75.

    Article  Google Scholar 

  10. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642–4649.

    Article  Google Scholar 

  11. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer Leukemia Group B. N Engl J Med 1994; 331: 896–903.

    Article  CAS  Google Scholar 

  12. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481–3485.

    Article  CAS  Google Scholar 

  13. Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Pentice AG et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009; 145: 598–605.

    Article  Google Scholar 

  14. Mrozek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman S et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 2012; 30: 4515–4523.

    Article  Google Scholar 

  15. Buchner T, Berdel WE, Woermann BJ, Sauerland MC, Heinecke A, Krug U et al. Upfront randomization 10 years later: The AML Cooperative Group Strategy. Blood 2014; 124: 2267.

    Google Scholar 

Download references

Acknowledgements

Ms Birgit Mayerhoffer and Sabine Jacob helped to prepare the typescript. RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to T Büchner.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Büchner, T., Krug, U., Peter Gale, R. et al. Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia. Leukemia 30, 1781–1784 (2016). https://doi.org/10.1038/leu.2016.54

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2016.54

This article is cited by

Search

Quick links